-
I have been a subscriber to Contraceptive Technology Update for many years and rarely take issue with the content. I must, however, register my total surprise and dismay at your 25 Events to Know in Reproductive Health that appeared in the January 2005 issue.
-
-
The rhythm strip shown in the figure was obtained from an elderly woman with a history of cardiomyopathy. She has a known history of bundle branch block (ie, RBBB). How would you interpret the rhythm?
-
There is little disagreement about the merit of treating frank hypothyroidism. Because of conflicting data, much less consensus exists about whether subclinical hypothyroidism (ie, elevated TSH levels with normal T4) should be treated. Since thyroid disorders increase with age, a population of advanced years is an appropriate group in which to evaluate this issue further.
-
A new agent has received expedited FDA approval for the treatment of relapsing multiple sclerosis.
-
Atenolol is unsuitable as a first-line drug in hypertension.
-
Pharmacotherapy of hypertension has been much in the news in the last 2 months. Standard therapies such as atenolol have been challenged, while calcium channel antagonists may be making a comeback.
-
Most neoplastic lesions are not detected either by Hemoccult screening or by multitarget analysis of fecal DNA. Nevertheless, the fecal DNA analysis was significantly more efficient than Hemoccult testing.
-
Maintaining INRs (International normalized ratios) between 2 and 3 is safer than INRs below 2, as suggested by some guidelines.
-
Researchers from Sweden performed a meta-analysis of 9 randomized, controlled trials that looked at the effectiveness of atenolol on cardiovascular morbidity and mortality in patients with hypertension.